Nakasato A - Search Results

1

Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique.

Mansfield C, Myers K, Klein K, Patel J, Nakasato A, Ling YL, Tarhini AA. Mansfield C, et al. Among authors: nakasato a. Future Oncol. 2021 Jun;17(17):2151-2167. doi: 10.2217/fon-2020-1193. Epub 2021 Mar 12. Future Oncol. 2021. PMID: 33709791 Free article.

2

Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.

Ghate SR, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS. Ghate SR, et al. Among authors: nakasato a. Curr Med Res Opin. 2018 Dec;34(12):2169-2176. doi: 10.1080/03007995.2018.1501351. Epub 2018 Aug 5. Curr Med Res Opin. 2018. PMID: 30009647

3

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.

Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberté F, Nakasato A, Burne R, Duh MS. Tarhini A, et al. Among authors: nakasato a. Melanoma Res. 2018 Dec;28(6):618-628. doi: 10.1097/CMR.0000000000000507. Melanoma Res. 2018. PMID: 30216199 Free PMC article.

4

Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study.

Tarhini A, Ghate S, Ionescu-Ittu R, Shi S, Nakasato A, Ndife B, Laliberté F, Burne R, Duh MS. Tarhini A, et al. Among authors: nakasato a. Future Oncol. 2019 Feb;15(4):359-370. doi: 10.2217/fon-2018-0671. Epub 2018 Oct 15. Future Oncol. 2019. PMID: 30317881

5

Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.

Betof Warner A, Tarhini A, Kang B, Nakasato A, Ling YL, Shah R, Tang J, Patel J. Betof Warner A, et al. Among authors: nakasato a. Melanoma Res. 2023 Feb 1;33(1):38-49. doi: 10.1097/CMR.0000000000000856. Epub 2022 Oct 15. Melanoma Res. 2023. PMID: 36545921

6

Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.

Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS. Ghate S, et al. Among authors: nakasato a. Melanoma Res. 2019 Jun;29(3):301-310. doi: 10.1097/CMR.0000000000000504. Melanoma Res. 2019. PMID: 30247203 Free PMC article.

7

Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.

Ghate SR, Li Z, Tang J, Nakasato AR. Ghate SR, et al. Am Health Drug Benefits. 2018 Oct;11(7):334-343. Am Health Drug Benefits. 2018. PMID: 30647822 Free PMC article.

8

Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.

Brunetto AL, Castillo LA, Petrilli AS, Macedo CD, Boldrini E, Costa C, Almeida MT, Kirst D, Rodriguez-Galindo C, Pereira WV, Watanabe FM, Pizza M, Benites E, Morais V, Gadelha A, Nakasato A, Abujamra AL, Gregianin LJ; Brazilian Collaborative On behalf of the Brazilian Collaborative Study Group of Ewing Family of Tumors EWING1 and the Brazilian Society of Pediatric Oncology SOBOPE. Brunetto AL, et al. Among authors: nakasato a. Pediatr Blood Cancer. 2015 Oct;62(10):1747-53. doi: 10.1002/pbc.25562. Epub 2015 Apr 27. Pediatr Blood Cancer. 2015. PMID: 25917418 Clinical Trial.

9

Effectiveness and Safety of Retreatment with ¹⁷⁷Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States.

Delpassand ES, Yazdi SM, Ghantoji S, Nakasato A, Strickland C, Nunez R, Shafie A, Cork S, Byrne C, Tang J, Patel J. Delpassand ES, et al. Among authors: nakasato a. J Nucl Med. 2024 May 1;65(5):746-752. doi: 10.2967/jnumed.123.265703. J Nucl Med. 2024. PMID: 38514088

10

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.

Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL; NET CTPM participants. Singh S, et al. J Natl Cancer Inst. 2023 Sep 7;115(9):1001-1010. doi: 10.1093/jnci/djad096. J Natl Cancer Inst. 2023. PMID: 37255328

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page